Clinical feasibility of chairside methylene blue-mediated photodynamic therapy for oral candidiasis Authors: Peiru Zhou, Furong Yang, Jiakun Fang, Jiangli Zheng, Yanhong Meng, Xu Zhang, Hong Hua Published: 2026 ABSTRACT AbstractObjectivesOral candidiasis is a common oral mucosal infection, and limitations of conventional antifungal therapy highlight the need for alternative chairside treatment approaches. This study aimed to assess the short-term clinical response, safety, and feasibility of a chairside methylene blue-mediated photodynamic therapy (MB-PDT) protocol for oral candidiasis, and to generate preliminary data to inform the design of future randomized controlled trials.MethodsThis prospective, randomized, open-label, exploratory controlled trial enrolled patients with clinically and mycologically confirmed oral candidiasis between September 2024 and September 2025. Participants were block-randomized into two groups: the MB-PDT group (n = 9), which received chairside MB-PDT using the Periowave® systemor, and the nystatin group (n = 9), which received nystatin lozenges (500,000 IU per lozenge). MB-PDT was administered three times weekly for two weeks, while nystatin lozenges were taken three times daily for two weeks. Clinical outcomes, mycological outcomes, comprehensive response, adverse events, treatment adherence, and follow-up completion were assessed over 14 days.ResultsEighteen participants were enrolled, with no significant baseline differences between groups (all P > 0.05). Both groups showed marked improvement in clinical symptoms and mucosal signs. Clinical response rates were 66.7% in the MB-PDT group and 88.9% in the nystatin group (P = 0.576). Mycological clearance rates were 44.4% and 88.9%, respectively (P = 0.131). Comprehensive response rates reached 88.9% in the MB-PDT group and 100.0% in the nystatin group (P = 0.094). No serious adverse events were reported. Two participants withdrew, yielding an overall dropout rate of 11.1%, with good treatment adherence.ConclusionsChairside MB-PDT using a portable Periowave® system was feasible and well tolerated in this pilot randomized trial, while its antifungal efficacy requires further evaluation in larger studies.Trial RegistrationChinese Clinical Trial Registry ID ChiCTR2400088856. Registration Date 28 August 2024.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12903-026-08721-9.Keywords: Oral candidiasis, Photodynamic therapy, Methylene blue, Pilot randomized controlled trial, Clinical feasibility Introduction Oral candidiasis is a common infectious disease of the oral mucosa caused by Candida species. It predominantly affects older adults and individuals with compromised immune function, including patients with human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), diabetes mellitus, and those undergoing chemotherapy or radiotherapy. Common risk factors include denture wearing, xerostomia, the use of broad-spectrum antibiotics, and immunosuppressed states [1]. Current management of oral candidiasis mainly relies on antifungal agents such as nystatin, fluconazole, and miconazole [2]; however, these treatments present several limitations [3]. Nystatin is often associated with unpleasant taste and local mucosal irritation, which may adversely affect patient adherence [4]. Rai et al. also reported that the bitter taste of nystatin is a common adverse effect during the treatment of oral candidiasis [5, 6]. In addition, prolonged use of systemic antifungal agents, such as fluconazole, may result in hepatotoxicity and nephrotoxicity, promote the development of antifungal resistance, and cause clinically relevant drug–drug interactions, including with anticoagulants [7–9]. Therefore, there is a clear clinical need to explore a safe, and well-tolerated local therapeutic approach that is suitable for chairside application. Photodynamic therapy (PDT) has emerged as a rapidly developing antimicrobial strategy in recent years. It exerts its effects through the generation of reactive oxygen species by a photosensitizer upon irradiation with light at a specific wavelength, leading to selective disruption of microbial cell structures. PDT is characterised by low systemic toxicity, a reduced risk of antimicrobial resistance, and a certain ability to disrupt biofilms. In the field of oral health, PDT has been applied as an adjunctive treatment for periodontal disease, oral leukoplakia, and root canal disinfection [10]. An increasing number of studies have also investigated the application of PDT in the treatment of oral candidiasis. Preclinical studies have demonstrated its antifungal efficacy; for example, Carmello et al. reported that Photodithazine-mediated PDT significantly reduced fungal burden in an immunosuppressed mouse model of oral candidiasis, achieving therapeutic effects comparable to those of nystatin [11]. Clinical studies and meta-analyses have further shown that PDT provides favourable outcomes in the management of oral candidiasis, with efficacy comparable to conventional antifungal agents in reducing Candida colonisation and improving clinical symptoms [12, 13]. Notably, in the treatment of palatal lesions associated with denture stomatitis, PDT has been reported to be superior to nystatin [12]. Recent reviews of clinical trials have also suggested that the combination of PDT with antifungal agents may further improve treatment outcomes [14]. Among various photosensitisers, methylene blue-mediated photodynamic therapy (MB-PDT) has attracted considerable attention owing to its well-established antifungal activity, favourable biocompatibility, and additional anti-inflammatory properties. Multiple clinical studies have demonstrated that MB-PDT effectively reduces Candida viability and biofilm burden, with enhanced efficacy observed when combined with adjuvants such as potassium iodide (KI) [15]. However, despite growing clinical interest, existing studies vary widely in PDT devices and irradiation parameters, and data on the clinical feasibility of standardized chairside MB-PDT systems remain preliminary. Based on a portable chairside MB-PDT system (Periowave®; Fig. 1), this study was designed as a small-sample, exploratory randomized controlled feasibility trial. The system employs a low-power 660 nm diode laser in combination with methylene blue, a photosensitizer with favourable biocompatibility. Uniform irradiation of the lesion area is achieved using an “O”-shaped mucosal light guide together with a mobile light-beam delivery technique, allowing the development of a standardized chairside protocol that can be readily integrated into routine clinical workflows. Portable Periowave® PDT system. A Main unit: control circuitry; B Main unit: laser generator; C Photosensitizer (methylene blue); D “O”-shaped mucosal light guide The aim of this study was to compare chairside Periowave® MB-PDT approach with conventional antifungal therapy in patients with oral candidiasis, and to preliminarily assess its short-term clinical response, safety, and feasibility, thereby generating preliminary data to inform the design of future large-scale randomized controlled trials. Materials and methods Study design and participants This study was a pilot, randomized, controlled, and open-label clinical trial designed to evaluate the clinical feasibility of chairside MB-PDT for oral candidiasis. Participants diagnosed with oral candidiasis who attended the Department of Oral Medicine at Peking University School and Hospital of Stomatology (Beijing, China) between September 1, 2024, and September 30, 2025, were prospectively screened and enrolled. Inclusion criteria Adults (> 18 years) with a clinical diagnosis of oral candidiasis according to established diagnostic criteria were eligible for inclusion [16]. Diagnosis was confirmed by the presence of compatible clinical signs and symptoms in combination with mycological evidence, including a positive smear for fungal elements and/or isolation of Candida species from oral specimens. Patients with common predisposing factors, including diabetes mellitus, prolonged antibiotic use, denture wearing, and poor oral hygiene, were eligible. Exclusion criteria Participants were excluded if any of the following criteria were met: (i) clinical evidence of systemic fungal infection other than oral candidiasis; (ii) known allergy or hypersensitivity to methylene blue or nystatin; (iii) pregnancy or lactation; (iv) significant hepatic dysfunction (alanine aminotransferase, aspartate aminotransferase, or total bilirubin > 1.5 times the upper limit of normal) or renal impairment (serum creatinine > 1.5 times the upper limit of normal), or the presence of other severe systemic diseases; (v) participation in another interventional clinical trials within 30 days before enrollment; (vi) receipt of systemic antifungal agents within 30 days or topical antifungal agents within 14 days before enrollment; (vii) a diagnosis of chronic mucocutaneous candidiasis or confirmed HIV infection; (viii) psychiatric disorders or other conditions likely to impair treatment adherence or cooperation; (ix) diseases associated with a marked reduction in salivary secretion. Randomization and grouping Participants were allocated to two groups via block randomization to achieve balanced allocation across groups. Randomization was managed by an independent biostatistician (Professor Sainan Zhu, Department of Medical Statistics, Peking University First Hospital). A fixed block size was used with a computer-generated random sequence, and assignment concealment was maintained using sequentially numbered, opaque, sealed envelopes (SNOSE). Intervention protocol Participants in the MB-PDT group received photodynamic therapy using the Periowave® PDT system (HHL-5000; Zhengzhou Jiatai Biotechnology Co., Ltd., China; Sino-Canadian joint venture). The system consists of a main unit (controller and laser generator), protective components, and a single-use treatment kit including a photosensitizer applicator, a replaceable “O”-shaped mucosal light-guide ring, and methylene blue (0.1 mg/mL) as the photosensitizer. Detailed technical specifications of the Periowave® photodynamic therapy system are provided in (Table 1). Table 1Technical specifications of the Periowave® PDT systemParameterSpecificationDescription/NotesManufacturerZhengzhou Gata Biotechnology Co., LTD (Sino-Canadian Joint Venture)Portable diode laser systemModelPeriowave® PDT deviceHHL-5000Light sourceDiode laserContinuous emissionWavelength660 ± 10 nm (red light)Peak absorption of methylene blueOutput power160–220 mWLow-level, non-thermalEnergy density1.2–3.3 J/cm2Calculated for 4–8 cm2 target areaSpot diameter0.8 cm/PhotosensitizerMethylene blue (MB)/Irradiation time60 ± 3 s per siteContinuous, mobile irradiationOperation modeHandheld, single-use optical tipPrevents cross-contaminationCooling systemPassive air coolingNo thermal effectsSafety featuresAutomatic shut-off, indicator lightComplies with GB7247.1-2012 Technical specifications of the Periowave® PDT system Before each treatment session, the target mucosal area was isolated and gently dried to remove saliva. Methylene blue (0.1 mg/mL) was then applied evenly to the lesion surface and allowed to incubate for 1 min. Using the fully assembled Periowave® handpiece, the target area was irradiated with a mobile light delivery technique, with an irradiation time of 60 ± 3 s per treatment area. After irradiation, residual photosensitizer was removed using cotton rolls or by rinsing with water. The treatment procedure is illustrated in Fig. 2. Participants received MB-PDT three times per week for two consecutive weeks. Procedure of chairside MB-PDT using the Periowave® system. A Preparation of materials, including the main unit, photosensitizer, assembled light-guiding tip, and protective eyewear; B application of the photosensitizer to the affected mucosal area; C mobile irradiation, with 1 min of light exposure per anatomical site Participants in the nystatin group were treated with nystatin lozenges (500,000 IU per lozenge; Zhejiang Zhenyuan Pharmaceutical Co., Ltd., China) three times daily for two weeks, providing a total daily dose of 1,500,000 IU, consistent with adult dosing recommendations for oral candidiasis [2]. A three times daily regimen was selected to improve patient adherence and convenience compared to the four-times-daily regimen commonly recommended in clinical guidelines. Additionally, in China, commercially available nystatin lozenges are formulated as 500,000 IU per lozenge, making three times daily dosing a practical approach in the clinical setting. The lozenges were allowed to dissolve slowly in the mouth and were then expectorated. Outcome measures Clinical symptoms and signs focused on pain/burning sensation, rate 0 = none, 1 = mild, 2 = moderate, 3 = severe. Mucosal atrophy, erythema, and/or pseudomembrane was scored 0–3 with area cutoffs: 0 = normal, no lesions; 1 = mild lesions (< 0.5 cm2); 2 = moderate lesions (0.5–1 cm2); 3 = severe lesions (> 1 cm2). These scores were applied to the various mucosal sites as illustrated in Figure S1, which depicts representative examples of each score. All clinical outcomes were assessed by a single experienced oral medicine clinician (Peiru Zhou) to ensure consistency in evaluation. Mycological assessment was performed using salivary culture: unstimulated saliva was inoculated onto Sabouraud dextrose agar (SDA) to support yeast growth. Colony-forming units (CFUs) were enumerated to quantify fungal burden. Species-level identification was performed using CHROMagarTM Candida, a chromogenic medium that differentiates Candida species by their characteristic colony colors. Outcomes Clinical efficacy and mycological efficacy were assessed independently. Because clinical improvement does not necessarily indicate complete fungal eradication, a comprehensive efficacy combining both parameters was also evaluated. Clinical efficacy Clinical efficacy was assessed using clinical endpoints and dichotomized as A0 (“clinically effective”, defined as a reduction in the grade of symptoms and/or signs) or A1 (“clinically ineffective”, defined as no reduction in symptom/sign grade) [17]. Mycological efficacy Mycological response was classified as: B0 (“eradication”, negative on fungal microscopy or no CFU of Candida species on culture]); B1 (“partial eradication”, at least one Candida species converting to negative on microscopy and/or a decrease in CFUs of Candida species on culture; B2 (“persistence” [continued fungal presence, with microscopy remaining positive and no reduction in CFU of Candida species in culture.]); B3 (“replacement” [the detection of new Candida species in culture in the absence of clinical symptoms or signs]); B4 (“reinfection” [the identification of new Candida species accompanied by clinical symptoms and/or signs]). Mycological response (“effective”) was defined as achieving B0 or B1, whereas “mycological clearance” was defined as B0. “Percent clearance” was calculated as the proportion of participants who achieved the B0 criterion. Comprehensive efficacy Comprehensive efficacy was categorized as follows: “cure”, defined as clinical effectiveness (A0) and fungal eradication or partial eradication (B0 or B1); “effective”, defined as clinical effectiveness (A0) or fungal eradication or partial eradication (B0 or B1); “ineffective”, defined as clinical failure (A1) and fungal persistence, replacement, or reinfection (B2–B4). “Response” was defined as meeting the criteria for either cure or effective. “Percent response” was calculated as the proportion of participants who met the response criteria. “Cure” was defined as meeting the criteria for cure only. “Percent cure” was calculated as the proportion of participants who met the cure criteria. Follow-up schedule Participants in the MB-PDT group were followed up six times over a two-week period, corresponding to three visits per week. Following baseline assessment on Day 0, the first MB-PDT session was administered. Clinical assessments and salivary fungal cultures were performed after the third and sixth treatment sessions. Participants in the nystatin group were followed up and underwent clinical assessments on Day 0, Day 7, and Day 14. Salivary fungal cultures were collected at the Day 7 and Day 14 follow-up visits. Calculation of sample size An initial sample size of nine participants per group was determined based on practical considerations for this exploratory, early-phase study, with the primary aim of assessing the feasibility of the intervention. As a pilot trial, no formal statistical power calculation was performed. Statistical analyses Statistical analyses were performed using SPSS version 22.0 (IBM, Armonk, NY, USA). Continuous variables are presented as mean ± standard deviation. Data normality was assessed using the Shapiro–Wilk test. Normally distributed data were compared using the independent-samples t test, while non-normally distributed data were analyzed using the Mann–Whitney U test. Categorical variables were compared using the χ2 test or Fisher’s exact test, as appropriate. All tests were two-sided, and a P value < 0.05 was considered statistically significant. The primary analysis was conducted according to the intention-to-treat (ITT) principle, with missing data due to loss to follow-up or withdrawal handled using the last observation carried forward (LOCF) method. Results Participant enrollment A total of 52 individuals were assessed for eligibility. Eighteen participants fulfilled the inclusion criteria and were subsequently enrolled. Using block randomization, they were allocated equally into two groups, with nine participants assigned to each group. Exclusions occurred due to ineligibility (n = 15) or refusal to provide informed consent for participate in the study (n = 19). During the intervention period, two participants were lost to follow-up for treatment-related reasons: one in the nystatin group withdrew due to poor taste and local irritation associated with nystatin lozenges, and one in the MB-PDT group withdrew after three PDT sessions because a salivary fungal culture remained positive and the participant perceived the treatment as ineffective. Consequently, 16 participants completed the study, and data from all 18 participants were included in the ITT analysis. The screening, randomization, intervention, and assessment of participants are summarized in (Fig. 3). CONSORT flow diagram of participant progression through the study. The diagram illustrates participant flow from screening through randomization, intervention, follow-up, and assessment. A total of 52 participants were screened, 18 were randomized into tow groups, and 16 completed the study. This flowchart was developed following the CONSORT 2010 guidelines for reporting randomized controlled trials [18] Characteristics of participants at baseline The baseline demographic characteristics and clinical data of the two groups are summarised in (Table 2). The mean age was 66.33 ± 11.68 years in the MB-PDT group and 63.11 ± 11.80 years in the nystatin group, with no statistically significant difference between groups (P = 0.568). The sex distribution was identical in both groups (3 males and 6 females in each group; P = 1.000). With respect to clinical symptoms and signs, there were no significant differences between the MB-PDT and nystatin groups in pain/ burning sensation score, erythema/ atrophy/ pseudomembrane score (all P > 0.05), indicating that the two groups were comparable at baseline. Table 2Demographic characteristics of participants at baselineVariablesMB-PDT Group(n = 9)Nystain Group(n = 9)P valueAge (mean ± SD)66.33 ± 11.6863.11 ± 11.800.568Sex (male / female)3/63/61.000Pain/ burning sensation score [Median (P25, P75)]1.0 (0.5, 2.0)1.0 (1.0, 2.0)0.489Mucosal atrophy/ erythema/ pseudomembrane score [Median (P25, P75)]1.0 (0.5, 1.5)1.0 (1.0, 2.0)0.387Underlying comorbidities* (yes/no)3/63/61.000Median (P25, P75) represents the median value, with P25 indicating the 25th percentile (lower quartile) and P75 indicating the 75th percentile (upper quartile)*Underlying comorbidities observed across the two groups included hypertension, hyperlipidemia, type 2 diabetes mellitus, asthma, and chronic atrophic gastritis Demographic characteristics of participants at baseline Median (P25, P75) represents the median value, with P25 indicating the 25th percentile (lower quartile) and P75 indicating the 75th percentile (upper quartile) *Underlying comorbidities observed across the two groups included hypertension, hyperlipidemia, type 2 diabetes mellitus, asthma, and chronic atrophic gastritis Clinical, mycological, and comprehensive efficacy of MB-PDT The intention-to-treat (ITT) analysis of clinical and mycological outcomes for both groups is presented in (Table 3). The clinical response rate was 66.7% (6/9) in the MB-PDT group and 88.9% (8/9) in the nystatin group, with no statistically significant difference between groups (P = 0.576). With regard to mycological outcomes, the mycological response rate was 55.6% (5/9) in the MB-PDT group and 88.9% (8/9) in the nystatin group (P = 0.136), while the fungal clearance rate was 44.4% (4/9) and 88.9% (8/9), respectively (P = 0.131). Although numerically lower rates were observed in the MB-PDT group, these differences did not reach statistical significance (P > 0.05), which may be attributable to the small sample size of this exploratory study. Table 3Comparison of clinical, mycological and overall treatment response between groupsOutcomesMB-PDT Group(n = 9)Nystatin Group(n = 9)P-value*Clinical efficacyResponse (%)66.7%(6/9)88.9%(8/9)0.576Mycological efficacyResponse (%)55.6%(5/9)88.9%(8/9)0.136Clearance (%)44.4%(4/9)88.9%(8/9)0.131Comprehensive efficacyResponse (%)88.9%(8/9)100.0%(9/9)0.094Cure (%)33.3%(3/9)77.8%(7/9)0.153*P-values were derived from χ2 tests Comparison of clinical, mycological and overall treatment response between groups *P-values were derived from χ2 tests In terms of overall efficacy, the combined response rate was 88.9% (8/9) in the MB-PDT group and 100.0% (9/9) in the nystatin group, with no statistically significant difference between groups (P = 0.094). The cure rates were 33.3% (3/9) and 77.8% (7/9) in the MB-PDT and nystatin groups, respectively, and the difference was not statistically significant (P = 0.153). Safety Safety was assessed through continuous monitoring and documentation of adverse events (AEs) and serious adverse events (SAEs) throughout the study period. No SAEs were reported. A total of two AEs were recorded. In the nystatin group, one participant discontinued treatment and withdrew from the study because of poor palatability and pronounced local irritation associated with nystatin lozenges. In the MB-PDT group, one participant experienced gingival redness and pain during treatment. Subsequent examination revealed abundant subgingival calculus at the affected tooth, consistent with periodontal disease. The symptoms resolved following scaling and root planing, and the investigator determined that the event was unrelated to MB-PDT. Apart from these events, no other intervention-related adverse reactions were observed in either group. Overall, the treatment regimens evaluated in this study were well tolerated, and no significant safety concerns were identified. Discussion In this randomized controlled study, we compared the short-term clinical response and safety of a chairside Periowave® MB-PDT system with those of nystatin in the treatment of oral candidiasis. After 14 days of treatment, both groups demonstrated marked improvements in clinical symptoms and signs compared with baseline. The MB-PDT group exhibited favourable clinical, mycological, and overall treatment response rates, with an overall response rate of 88.9%. However, for key mycological outcomes—including mycological response, fungal clearance, and overall cure rates—the MB-PDT group showed numerically lower values than the nystatin group. Although these between-group differences did not reach statistical significance, the results indicate that, under the treatment parameters and duration applied in this pilot study, MB-PDT achieved a more limited degree of fungal reduction compared with standard antifungal therapy. Importantly, no serious adverse events directly attributable to Periowave® MB-PDT were observed throughout the study. The intervention was well tolerated, and its favourable safety profile supports the feasibility of Periowave® MB-PDT as a chairside local treatment approach for oral candidiasis. The MB-PDT protocol used in this study can be summarized as follows: methylene blue (0.01%) was applied topically to the lesion, followed by irradiation using the portable Periowave® system with a red light source (wavelength: 660 nm, power: 160–220 mW, energy density: 1.2–3.3 J/cm2) for 1 min per session. Treatments were administered three times per week for two weeks. Clinicians should ensure that lesions are accessible for light delivery and consider combining MB-PDT with standard antifungal therapy for more extensive or refractory cases. This protocol provides a feasible framework for chairside application in patients with mild to moderate oral candidiasis, although further studies are needed to optimize parameters and validate efficacy in larger patient populations. In recent years, PDT has been considered a potential adjunctive or alternative antifungal strategy due to its selective fungicidal activity, minimal damage to host tissues, and low risk of inducing antimicrobial resistance. In vitro studies have demonstrated that the antifungal efficacy of PDT is influenced by multiple factors, including the type and concentration of the photosensitizer, incubation time, and irradiation parameters. Moreover, the antifungal effects can be further enhanced by the addition of inorganic salts or efflux pump inhibitors [19–21]. In immunosuppressed animal models, PDT administered under optimized conditions has been shown to effectively suppress Candida viability and reduce mucosal or tissue colonization, [22–25] providing a biological rationale for its application in oral candidiasis. In line with these preclinical observations, MB-PDT in the present study was associated with improvements in mucosal erythema, atrophy, and patient-reported discomfort. At the clinical level, available evidence for PDT in oral candidiasis is unevenly distributed, with most studies concentrating on denture stomatitis or HIV-associated Candida infections. Schwingel et al. demonstrated that a single session of MB-PDT achieved complete eradication of oral Candida in HIV-positive patients, with a low recurrence rate maintained over a 30-day follow-up period [26]. Similarly, Mima et al. reported that Photogem-mediated PDT achieved clinical efficacy comparable to that of nystatin, while significantly shortening the treatment duration [27]. In another study, Afroozi et al. demonstrated that PDT combined with nystatin resulted in a greater reduction in Candida colony counts compared with nystatin monotherapy [28]. Our group has also previously achieved satisfactory lesion reduction and symptom relief using 5-aminolevulinic acid–PDT (ALA-PDT) in patients with chronic hyperplastic candidiasis [29, 30]. In contrast, other studies have reported less favourable outcomes. For example, MB-PDT combined with low-level laser therapy yielded lower cure rates and higher recurrence rates than miconazole gel [31]. This highlights the variability of results across different treatment regimens and patient populations. Furthermore, while conventional photosensitizers such as methylene blue and porphyrin derivatives, several natural photosensitizers have also been explored in photodynamic therapy. One notable example is curcumin, a polyphenolic compound derived from Curcuma longa. Curcumin-mediated PDT has demonstrated inhibitory effects against Candida species in both in vitro and experimental studies, owing to its antimicrobial, anti-inflammatory, and anticancer properties [32–36]. However, its broader clinical application remains limited by poor aqueous solubility, rapid photodegradation, and relatively low bioavailability [35]. In comparison, methylene blue is a well-established photosensitizer with stable photochemical properties, favourable tissue penetration, and more standardized clinical protocols, which may make it more suitable for routine chairside clinical use. Consistent with these findings, our study revealed that improvements in clinical symptoms and signs were more evident than mycological responses, with fungal clearance remaining limited under the treatment parameters and duration applied. This highlights the complexity of achieving complete fungal eradication with MB-PDT. Importantly, Candida species can be cultured from the oral cavity of healthy individuals, with colonization reported in up to one-third of the population. Therefore, culture positivity alone does not necessarily indicate active infection and should be interpreted in conjunction with clinical findings. Collectively, these findings suggest that although MB-PDT may provide reproducible benefits in alleviating clinical manifestations of oral candidiasis, its capacity to achieve complete fungal eradication may be constrained by factors such as short treatment duration, restricted cumulative light exposure, disease subtype, photosensitizer concentration, and lesion depth. Regarding safety, adverse effects associated with PDT reported in the literature are generally mild and transient, including oral irritation or nausea, and are primarily related to photosensitizer taste or mucosal sensitivity. In our study, one participant in the MB-PDT group developed gingival redness and swelling attributable to pre-existing periodontal disease; symptoms resolved following routine periodontal therapy, and the event was adjudicated as unrelated to MB-PDT. Overall, the safety findings of the present study are consistent with previous reports. Clinical studies evaluating the application of Periowave® system for oral candidiasis remain limited, and randomized controlled evidence is scarce. To our knowledge, this study represents one of the first randomized controlled investigations to preliminarily examine the clinical performance and feasibility of a chairside Periowave® MB-PDT protocol for oral candidiasis. The results indicate that, although the mycological response and fungal clearance rates in the MB-PDT group were numerically lower than those observed with nystatin, MB-PDT was associated with marked improvements in mucosal erythema, atrophy, and other clinical signs, with overall treatment response rates approaching those of the nystatin group. These findings suggest that symptom and sign improvement may precede mycological eradication. This observation may be attributable to the physicochemical properties of methylene blue and the characteristics of the light source used. The reactive oxygen species generated during MB-PDT predominantly affect superficial mucosal layers and early-stage biofilms, while penetration into deeper biofilm structures and hyphal forms may be limited. Consequently, local inflammation and superficial Candida burden may be reduced earlier, whereas complete fungal eradication within a short treatment period may be more difficult to achieve. This observation is consistent with previous experimental studies showing that antimicrobial photodynamic therapy may significantly reduce Candida viability and biofilm biomass without necessarily achieving complete eradication. For example, photodynamic treatment has been shown to inhibit and disrupt biofilms formed by multidrug-resistant Candida auris and other Candida species, suggesting that PDT can effectively suppress fungal growth even in multidrug resistant strains [37, 38]. In addition, in vitro studies using different photosensitizers have demonstrated substantial reductions in Candida colony counts and biofilm formation following PDT, although the protective structure of mature biofilms may limit complete fungal elimination [39]. These findings support the interpretation that PDT may primarily reduce fungal burden and inhibit proliferation rather than immediately sterilizing infected tissues, which may explain why clinical improvement can occur even when complete mycological clearance is not achieved within a short treatment period. In this context, MB-PDT may have potential as a supportive chairside local intervention for mild to moderate oral candidiasis, or as a complementary approach alongside conventional antifungal therapy, pending further validation in larger-scale randomized controlled studies. This study has several strengths. First, a randomized controlled design was adopted, with standardized irradiation parameters and predefined outcome assessment criteria. Both clinical and mycological responses were evaluated, allowing a more comprehensive characterization of the short-term treatment effects of the chairside Periowave® MB-PDT system. Second, patient recruitment and follow-up completion rates were high, and no major procedural difficulties or adherence issues were encountered, supporting the clinical feasibility and operability of Periowave® MB-PDT in an outpatient setting. Nevertheless, several limitations should be acknowledged. Owing to the small sample size, this pilot study was not statistically powered to formally evaluate equivalence or non-inferiority between MB-PDT and nystatin. Consequently, definitive comparative conclusions cannot be drawn. As an exploratory trial with a limited sample size, a formal non-inferiority analysis was not performed. In addition, the relatively short treatment duration (14 days) precluded assessment of recurrence and long-term Candida colonization. Finally, key MB-PDT parameters—including photosensitizer concentration, incubation time, light dose, and irradiation frequency—were not systematically optimized; therefore, the observed treatment responses reflect the predefined parameter settings applied in this study. Additionally, the long-term effects of MB-PDT on soft tissue health need to be systematically evaluated. Future investigations should involve larger sample sizes, extended follow-up periods, and a non-inferiority design. Moreover, optimization strategies, such as dose escalation, prolonged treatment courses, refined irradiation protocols, and combination approaches with local or systemic antifungal therapies, should be systematically explored. This would help further elucidate the clinical role and therapeutic potential of MB-PDT for oral candidiasis, as well as address the impact of extended therapy on soft tissue integrity. Conclusions This pilot randomized study suggests that chairside MB-PDT using a portable Periowave® system is feasible and well tolerated in patients with oral candidiasis, with improvement in clinical manifestations. However, given the small sample size, short follow-up, and exploratory design, no definitive conclusions regarding antifungal efficacy or comparative effectiveness can be drawn, and further adequately powered studies are warranted. Supplementary information Supplementary Material 1. Acknowledgements The authors would like to express their sincere gratitude to Professor Sainan Zhu from the Department of Medical Statistics, Peking University First Hospital, for her expert assistance with the statistical analysis conducted in this study. Abbreviations Methylene Blue–Mediated Photodynamic Therapy Photodynamic Therapy Human Immunodeficiency Virus Acquired Immunodeficiency Syndrome Sabouraud Dextrose Agar Colony-Forming Unit Intention-to-Treat Last Observation Carried Forward Adverse Event Serious Adverse Event Authors' contributions All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Peiru Zhou, Furong Yang, Jiakun Fang, Jiangli Zheng, Yanhong Meng, Xu Zhang, and Hong Hua. The first draft of the manuscript was written by Peiru Zhou, Furong Yang, Xu Zhang and Hong Hua, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Funding This work was supported by the National Natural Science Foundation of China (NO. 82572435); the Program of New Clinical Techniques of Peking University School and Hospital of Stomatology (NO. PKUSSNCT-24A10). Peiru Zhou is supported by the Beijing High-Level Innovation and Entrepreneurship Talent Support Program, Young Backbone Talent Projects (NO. G202531217). Data availability The raw data supporting the findings of this study are available in the Zenodo repository at https://doi.org/10.5281/zenodo.18366001. Declarations Ethics approval and consent to participate This study was conducted in accordance with the ethical principles of the Declaration of Helsinki, originally adopted in 1975 and most recently revised in 2024. The protocol for this study was approved by the Ethics Committee of the Peking University School and Hospital of Stomatology (approval no. PKUSSIRB-2024101124). The trial was registered at the Chinese Clinical Trial Registry (ChiCTR) under the registration number ChiCTR2400088856 (registration date: 28 August 2024). The participants were informed of the purpose and procedure of the study and provided written consent after being assured that declining participation would not negatively impact their care. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Peiru Zhou and Furong Yang contributed equally to this work. Contributor Information Xu Zhang, Email: zhangxulove@bjmu.edu.cn. Hong Hua, Email: honghua1968@aliyun.com. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The raw data supporting the findings of this study are available in the Zenodo repository at https://doi.org/10.5281/zenodo.18366001.